基于Poly-PK策略的多组分药物研究  

Study on Multicomponent Drugs based on Poly-PK Strategy

作　　者：王洋 温丽荣 林思彤 池逸 林景超 Wang Yang;Wen Lirong;Lin Sitong;Chi Yi;Lin Jingchao(Metabo-Profile Biotechnology (Shanghai)Co.,Ltd.,Shanghai 201203,China)

机构地区：[1]麦特绘谱生物科技(上海)有限公司,上海201203

出　　处：《世界科学技术-中医药现代化》2018年第8期1459-1464,共6页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金委青基金项目(31500954):胆汁酸代谢对饮食诱导的肥胖型肠道菌群结构的作用机制研究;负责人:郑晓皎;国家自然科学基金委青年基金项目(31501079):基于"半聚焦"代谢组学策略的主要消化系统肿瘤共有和特有代谢模式研究;负责人:陈天璐

摘　　要：在创新中药及现代复方中药研究中,药代动力学研究始终发挥着重要作用,单体活性成分的药代动力学研究已较为成熟,而多组分药物成分之间协同或者拮抗作用及药物与机体的相互作用却使得多组分药代动力学研究极具挑战性。目前尚缺乏符合中药自身特征的药代动力学研究策略与评价体系,本文围绕多组分药代动力学研究策略展开,从Poly-PK策略的提出、初步验证到运用于临床研究进行详细概述。The study of pharmacokinetic plays an important role in the modern study and innovation of traditional Chinese medicine.The pharmacokinetic study of monomeric active component or several components has been mature.However,the synergistic or antagonistic effects of multicomponent drugs and the interactions between drugs and the body make the study of multicomponent pharmacokinetics extremely challenging.Currently,the pharmacokinetic strategy and evaluation system cannot meet with the characteristics of traditional Chinese medicine.This paper focused on the proposal of Poly-PK strategy,preliminary verification and clinical research.

关 键 词：多组分药物 药代动力学 代谢组学 Poly-PK研究策略 

分 类 号：R285.1[医药卫生—中药学]